let cooler head prevail initi outperform
initi coverag outperform rate price target base
view signific commerci potenti compani main asset
evalu clinic trial gaucher diseas gd type
parkinson diseas pd patient mutat appli
in-licens technolog use zolgensma sma enabl gene deliveri
broad brain-wid biodistribut approv target
therapi gba-rel diseas pd gba mutat repres
pd patient also evid suggest gba mutat predict worsen
prognosi pd manifest may encourag physician appli earli
initi diagnosi pd detail insid
aav-bas precis medicin gene therapi compani focus
neurodegen diseas prvl lead drug candid current
studi parkinson diseas pd mutat affect
around pd patient us anoth potenti indic gaucher
diseas rare inherit lysosom disord caus autosom recess
inherit gene
plan initi trial ultra-
rare diseas affect infant result short life expect
believ indic shorter regulatori pathway compar
indic estim approv clinic success
may happen given lack treatment patient
use gene deliveri technolog licens
technolog zolgensma use treatment sma diseas enabl
gene deliveri broad brain-wid biodistribut although
mechan regul homeostasi -synuclein
poorli understood enhanc activ reduc -synuclein
burden may potenti slow prevent neuron death
expect provid shortcut regulatori approv creat clinic
bridg pd develop assum potenti high price
per singl inject may limit use sever mutat
pd-gba howev estim signific market opportun
sale pd-gba risk-unadjust sale
found dr asa abeliovich current ceo orbim
silverstein foundat parkinson gba key sharehold
estim risk-adjust basi worth per dilut
share base dcf valuat move ahead
trial improv risk adjust may unlock signific valu sharehold
year price histori
neurodegen
novel biolog gene
treat parkinson diseas
neurodegen diseas
compani
found asa
abeliovich juli
headquart new york ny
analyst certif import disclosur see disclosur
outperform rate base belief share
under-valued accord evalu compani
main asset clinic trial
parkinson diseas pd gaucher diseas gd patient
around us pd patient mutat pd-gba
pd-gba patient prognosi less favor compar
idiopath pd current approv treatment
pd-gba gd type diseas believ
reason chanc secur fda approv gene
therapi treat pd-gba indic
activ demonstr propel provid clinic
period updat propel provid
updat preclin program
updat propel pd-gba recruit
biomark
data propel trial
provid trial gaucher diseas type
data provid trial
progress trial gaucher diseas
file frontotempor dementia
posit differenti activ propel provid
advanc pipelin asset
acquisit signific premium
financ greater
expect
activ propel provid trial disappoint
propel clinic trial take longer expect and/or
competit landscap parkinson diseas
price target base dcf valuat methodolog assum wacc residu
growth rate anticip launch peak sale patent expir forecast ww
risk-adjust sale driven parkinson diseas indic probabl success
key downsid risk price target clinic develop regulatori risk addit risk includ build
commerci infrastructur parkinson diseas indic higher anticip competit parkinson diseas
initi coverag prevail outperform rate
price target base view signific commerci potenti
compani main asset evalu clinic trial gaucher
diseas type parkinson diseas mutat pd-gba
patient price target suggest upsid potenti current trade level
aav-bas precis medicin gene therapi compani focus
neurodegen diseas use gene deliveri technolog licens
technolog avexi acquir novarti
use treatment sma diseas vector enabl gene deliveri
broad brain-wid biodistribut singl administr
prvl lead drug candid current studi parkinson diseas
pd glucocerebrosidas mutat affect around pd patient
us american preclin program mous model
non-human primat demonstr consist widespread biodistribut
signific increas enzym activ reduct lipid accumul
improv motor function
anoth potenti indic gaucher diseas gd rare inherit
lysosom storag disord caus autosom recess inherit mutat
gene inadequ enzymat activ caus progress accumul lipid
lysosom macrophag liver spleen bone bone marrow estim
gd patient us
three type gd type common case non-
neuronopath type gd success manag enzym replac
therapi er type show neurolog patholog repres
gd case respect indic rare unmet medic need
plan initi trial given
ultra-rar diseas estim patient us affect infant
result short life expect less two year despit best support care
think indic may offer shortest regulatori pathway rel
potenti indic estim regulatori approv clinic
success may grant given lack treatment patient
evid direct link mutat develop
parkinson diseas pd although mechan regul
homeostasi -synuclein remain poorli understood enhanc activ
result reduct -synuclein burden may potenti slow even prevent
neuron death therefor believ reason chanc address
need gba-mut pd patient wors clinic prognosi
mutant idiopath pd patient think indic may provid shortcut
regulatori approv creat clinic bridg pd develop
estim may approv pd-gba indic even though
regul may author use pd patient expect
rel high potenti price gene therapi estim per one-tim
treatment may limit use sever mutat repres pd-
gba howev still estim signific market opportun sale pd-
gba un-risk-adjust sale
given share genet link pd-gba estim probabl
success indic although estim pd-gba trial would take
third expect indic gaucher diseas type anoth
neuronopath lysosom storag disord similar later onset clinic
symptom patient present clinic heterogen manifest similar
patient go develop evid neurolog symptom resembl
patient later cours diseas
model regulatori approv launch indic
estim probabl success un-risk-adjust sale
summari recent yet compel histori found
collabor effort asa abeliovich ph current ceo orbim
own stock silverstein foundat parkinson gba
whose founder co-head global privat equiti orbim jonathan silverstein
disclos diagnosi parkinson diseas gba mutat
risk-adjust basi valu per dilut share base
dcf valuat methodolog moreov move forward trial
pd-gba improv risk adjust may unlock signific valu stock
price target base dcf valuat
methodolog assum weight averag cost capit wacc
residu growth rate view appropri given
gene therapi asset may need financ
multipl patent expir expect possibl late
end cash cash equival quarterli cash burn
prvl current market capit around base basic share
around base potenti dilut share
includ prvl pre-clin candid
valuat analysi re-assess contribut prvl valuat if/when
asset move clinic stage
assum probabl success po secur fda/ema
approv pd-gba patient
po indic peak penetr us market
although may seem unexpect assign po technic
preclin asset expect gene therapi address signific unmet
need life expect less two year face shorter regulatori
path view zolgensma enter clinic bla-readi
relev compar technolog
regulatori point view
po pd-gba indic peak penetr sever
pd patient popul think direct link
pd-gba prove clinic viabil would
direct implic pd-gba trial
po peak penetr patient popul
consid rel lower vs pd-gba prioriti
may less commerci potenti pd-gba may
requir larger longer trial indic
ex-u row revenu estim assum multipl factor
consist ex-u proport sale compar compani market
rel high price-tag drug medic devic
key downsid risk price target includ clinic develop risk
trial gd pd-gba patient addit risk come build
commerci infrastructur support pd indic post-regulatori approv
grant lower expect sale due higher anticip competit
failur gain support physician commun us/ex-u payer
given potenti premium price believ signific risk
govern commerci payer may limit adopt
may also requir substanti addit fund pre-launch commerci
oper form dilut equiti
see small-cap gene therapi compani potenti acquisit target larg
biopharma compani compani may appeal potenti acquir attract
target given out-licens collabor own world-wide
right asset
upcom catalyst includ updat on-going random double-
blind sham procedure-control propel studi moderate-to-sever pd
patient biomark readout includ gcase
synuclein nfl neurofila dat spect csf blood subsequ
expect see interim data propel
also expect enrol patient provid open label
trial subsequ month key biomark readout gcase glucer glusph
csf blood
catalyst includ initi open label progress studi
ind file frontotempor dementia grn mutat
exhibit catalyst calendar
histori stock price ownership
prvl stock price ltm vs nbi
current institut ownership septemb repres stock
top institut investor includ orbim
other
prvl ceo asa abeliovich other
exhibit top institut top insiders/stakehold septemb
stock price movement sinc compani ipo june impli stock
appreci driver may includ preclin clinic updat pd-gba gd
exhibit stock price histori sinc ipo june
factset oppenheim co note result view indic futur result
sec file appear need financ oper
includ run pd-gba gd trial
think interim result pd-gba and/or gd trial expect
subsequ rise stock price may allow rais equiti financ howev
trial result mute subsequ financ may achiev possibl
collabor larg biopharma partner
event pd-gba gd trial show subpar result may
reconsid clinic develop strategi opinion
clinical-stag gene therapi compani focus appli human genet
develop commerci disease-modifi aav-bas gene therapi
neurodegen diseas use precis medicin approach
neurodegener studi gene therapi genet defin patient
popul opinion precis medicin strategi appear increas
probabl clinic success
prvl lead candid treatment parkinson diseas
mutat pd-gba neuronopath gaucher diseas addit
work preclin develop gene therapi number
neurodegen diseas includ treatment frontotempor
dementia grn mutat treatment synucleinopathi
prvl somewhat differenti approach develop gene therapi
neurodegen diseas design select target diseas correspond
patient popul treat increasing/decreas express
particular gene precis select patient popul well-suit gene therapi
prvl gene therapi intend one-tim treatment address
presum underli genet mutat drive diseas progress
exhibit prvl pipelin current focus also includ preclin asset
prvl lead candid design treat patient pd-gba
neuronopath gd pd-gba affect total parkinson diseas popul
world-wide estim patient us gaucher diseas among
common lysosom storag disord estim us preval
patient neuronopath gaucher diseas patient exhibit neurolog
manifest addit non-cn manifest gaucher diseas
repres approxim gd patient us
pd-gba gd share underli genet mutat gene
glucocerebrosidas believ pd-gba continuum neuropath gd
patholog symptom sever manifest pd-gba gaucher
diseas depend level enzym defici driven sever
number mutat
exhibit gba gene multipl mutat associ pd
clark et al mutat glucocerebrosidas gene associ early-onset parkinson diseas
encod lysosom enzym beta-glucocerebrosidas gcase pd-gba
patient may mutat one chromosom copi gd patient may
mutat chromosom copi mutat lead
defici gcase result non-cn manifest gd well lysosom
dysfunct cell may lead inflamm neurodegener
symptom pd-gba neuronopath gd patient
current appli enzym replac therapi ert restor gcase
effect treatment non-cn manifest gd ert cross
blood-brain barrier bbb treat neurodegener
design express patient cell hypothesi
moa restor may slow stop diseas
progress pd-gba neuronopath gd patient
exhibit mechan action pd-gba base restor slow stop diseas progress
prvl current program util aav gene therapi technolog appear
well-design treatment diseas aav-bas viral vector
observ variou clinic trialszolgensma nv vy-aadc appear
well-toler pois deliv stabl long-last transgen express
mention initi report aav gene deliveri platform one
advanc technolog engin optim deliv aav-bas gene
therapi potenti durabl efficaci follow singl administr
differ serotyp aav far identifi
commonli use serotyp differ tropism make aav
applic system preferenti transduc specif cell type
immun privileg site increas likelihood efficaci
reduc risk neg immun respons deliveri local target
deliveri potenti requir lower dose system deliveri moreov
aav known caus diseas human aav gene therapi readili
integr genom target cell reduc potenti develop cancer
result treatment
specif chose base biolog properti track record
promin exampl applic zolgensma in-licens
zolgensma clinic trial type sma observ
enabl gene deliveri broad brain-wid biodistribut singl
similar avx also in-licens technolog
pursuant grant exclus world-wide licens use deliv
gene encod number diseas
gd heterogen lysosom storag disord character multi-organ
patholog gd may impact liver spleen hematopoiet system bone lung
gaucher diseas patholog character accumul sphingolipid
glucosylceramid degen chang
gaucher diseas among common lysosom storag disord
estim global preval one per substanti higher
incid individu ashkenazi jewish descent significantli higher
preval per
gaucher diseas three subtyp distinguish presenc absenc
neurolog symptom sever symptom age onset age death
type non-neuronopath gd common form
diseas repres gd case occur age involv
symptom includ enlarg liver enlarg spleen anemia bone patholog
type repres less gd case us present
infanc affect involv rapidli progress neurodegener
lead death infanc earli childhood
type repres approxim gd case us present
childhood adulthood affect involv neurolog symptom
gaze motor abnorm ataxia spastic myoclonu
exhibit spectrum clinic manifest gd
type type gd togeth refer neuronopath also result sever
system manifest seen type gaucher diseas patient although
rel rare us neuronopath gd make higher percentag gd
patient certain non-western countri includ japan korea egypt india china
believ given lower incidence/preval number compar non-western
countri gd commerci opportun less attract compar pd-
gba larg patient popul us
howev regulatori strategi point view develop may allow
secur faster fda/ema approv thu enabl earlier access
pd-gba indic inform physician patient includ via spontan
commerci use clinic trial even formal regulatori approv grant
current potenti treatment option gd
therapi approv fda treatment sever
ert consist recombin gcase approv treatment
includ cerezym sni vpriv tak elelyso ert howev cross
bbb blood-brain barrier treat neurolog manifest ert
limit patient continu experi bone pain thrombocytopenia spleen
enlarg spleen lung patholog follow long-term ert treatment
multipl small molecul drug candid develop address
gd symptom howev believ symptomat treatment may
limit gene therapi may potenti posit effect
parkinson diseas pd affect estim american men women though
slightli common men pd caus combin genet
environment factor age main risk factor cure
multipl symptomat treatment medic exercis nutrit surgic
treatmental potenti reduc symptom improv qualiti life
common symptom pd includ tremor bradykinesia muscl rigid postur
instabilityal refer motor symptom pd also non-motor
symptom includ depress anxieti apathi fatigu sexual dysfunct
initi stage pd within first sever year diagnosi medic
levodopa usual control symptom major patient diseas
progress pd patient may need take medic increas
diseas durat increas peopl pd may notic throughout typic day
experi period adequ symptom control time period
symptom much notic time period peak medic
level usual hour take medic dose produc involuntari movement
dyskinesia patient chang one three state anoth
said motor fluctuat
sever gene therapi compani includ focus increas
therapeut window time deliv gene therapi directli brain
howev prvl approach appear differ compani view pd diseas
whole brain multipl clinic manifest clinic symptom pd may
appear earli year actual diagnosi pd
exhibit parkinson diseas prodrom activ clinic diagnosi period
dont consid direct competitor focus
rather earlier-stag pd popul wherea axgt/vygr
run clinic trial idiopath pd patient advanc stage
relationship gcase dysfunct -synuclein aggreg
believ role mutat gcase develop pd
dementia lewi bodi multipl studi taken place
somewhat increas interest therapeut potenti target gcase --
synuclein pathway given possibl associ sporad form pd
led acknowledg gcase valid target diseas modif
michael foundat parkinson research
avail evid shown -synuclein interact membran lipid
influenc -synuclein structur trigger format neurotox oligomer -sheet
conform one hand membran surfac might enabl local increas
synuclein concentr stimul accumul convers chang protein
conform could induc directli membran bind gcase involv
sphingolipid metabol hydrolyz glycolipid glccer glcsph gcase
catabol glccer glucos ceramid recycl gener new
glycosphingolipid sphingomyelin mutat reduc enzymat function
gcase lead accumul undigest substrat glccer lipid
exhibit mechan involv patholog gcase -- synuclein cross talk
despit pd clinic indistinguish
idiopath pd believ pd carrier mutat like
present aggress diseas cours
hypothesi also support fact deep brain stimul
db patient believ advanc stage pd mutat
carrier wherea pd popul believ
base publish literatur gba-mut pd patient differ idiopath pd
patient base number clinic symptom includ
year earlier onset pd
higher risk dementia
higher risk onset younger age
higher risk depression/anxieti
evid cortic activ confirm imag
although mutat quit common pd sever mutat affect
clinic symptom base publish literatur sever vs mild gba mutat may lead
worsen clinic manifest differ sever vs mild
year earlier age onset
higher risk dementia
higher risk visual hallucin
reduc cortic activ confirm imag
believ assum clinic differ sever vs mild gba mutat may lead
limit commerci adopt gene therapi mild gba mutat may
unconfirm unclear clinic featur support gene therapi
estim base publish literatur pd-gba mutat
sever therefor primari clinic commerci target
still repres signific patient popul us pd-gba patient
potenti disease-modifi single-dos treatment pd-gba
neuronopath gd gene therapi util viral vector deliv
codon-optim dna encod wild-typ gcase patient cell
mutat associ spectrum disord includ pd-gba
gd pd-gba gd presum result core biochem
mechan mani preclin model relev diseas
use three mous model studi amelior gcase defici
associ phenotyp
pharmacolog model conduritol -- epoxid cbe pharmacolog
inhibitor gcase mice treat cbe display phenotyp consist
gcase loss function includ lipid accumul motor behavior
abnorm neuropatholog interestingli vari cbe dosag
degre gcase inhibit possibl project degre enzym
defici seen pd-gba differ gd type
genet model model pd-gba gd combin mutat
mutat gene encod saposin essenti activ gcase
combin design lead sever reduct gcase
enzym activ phenotyp relev pd-gba gd includ
motor behavior abnorm -synuclein accumul neuropatholog
transgen defici murin -synuclein mutat
associ famili pd human mice display rel subtl
phenotyp includ reduc gastrointestin motil variabl motor
abnorm six month age
dose-find studi three separ dose administ cbe mice
intracerebroventricular icv inject intra-cisterna magna icm inject
possibl mice
three dose vector genom detect brain spinal cord five week
administr gcase activ reduc cbe-treat mice increas
highest dose cbe-treat mice also demonstr accumul
toxic glycolipid glucer glusph brain reduc
also caus impact mice behavior cbe-treat mice exhibit reduc
perform test motor function rotarod taper beam highest dose
result statist signific improv motor function
addit lysosom dysfunct pd-gba thought lead neuro-inflamm
process includ abnorm increas astrocyt astrogliosi microglia
microgliosi cbe induc reactiv astrogliosi confirm glial scar
microgliosi attenu
exhibit observ reduc reactiv astrogliosi microgliosi
studi use genet mous model show vector genom
presenc statist signific increas gcase activ cerebr cortex
mous model display repres phenotyp pd-gba neuronopath
gd due known limit preclin mous model data mous
model may may fulli reflect potenti efficaci pharmacolog
model cbe administ mice known inhibit gcase genet model
mutat activ gcase saposin reduc gcase activ despit
limit anim model evid increas gcase activ
reduc glycolipid accumul attenu behavior phenotyp
eventu support regulatori interact develop
neg histopatholog find toxic evid
mention mous model relat
defect lysosom recycl result gcase defici believ result
accumul -synuclein protein symbol enzym parkinson diseas
accord multipl public glycolipid substrat accumul context
gcase insuffici may directli interact -synuclein caus increas
aggreg toxic
-synuclein model observ trend toward increas level insolubl
synuclein protein cerebr cortex mice administr via icv
inject show suppression/accumul insolubl -synuclein week
also studi level hmw high molecular weight -synuclein
mous model treat cbe reduct hmw -synuclein aggreg
treatment cbe-dos mice
exhibit observ reduc hmw -synuclein aggreg -synuclein mous model
accord publish literatur increas level gcase activ lead reduct
accumul -synuclein protein ran vitro studi hela cell
human cell line mous hippocamp neuron cultur studi saw
administr result increas gcase activ reduc
safeti biodistribut non-human primat
ran safeti biodistribut studi healthi non-human primat
nhp nhp select studi similar human
possibl deliv via icm inject intend rout
administr plan clinic trial
studi includ nhp receiv one three treatment vehicl low
dose high dose plan use safeti biodistribut result
nhp studi inform dose select clinic trial
exhibit safeti biodistribut nhp support dose select clinic trial
overal nhp studi demonstr continu broad gcase protein express
nhp treat via icm inject
base biodistribut efficaci data nhp mous studi
believ administ via icm inject potenti increas gcase
non-patholog level target patient popul
prvl clinic develop gd patient includ open label trial
plan open label trial
clinic trial gaucher diseas type type
open-label studi patient enrol patient
trial includ patient infant two mutat
confirm diagnosi
primari endpoint trial includ safeti toler secondari outcom
includ biomark includ gcase glucer glusph blood csf
well clinic efficaci endpoint appropri neuronopath gd
exploratori endpoint includ addit biomark -synuclein nfl dat
spect mri chang baselin glucer glusph gcase enzym activ
measur csf blood month per fda requir
patient follow total five year monitor safeti select biomark
efficaci measur
like initi trial patient
trial includ patient two mutat confirm diagnosi
primari endpoint similar trial addit
exploratori endpoint behavior cognit gross motor qualiti life etc
clinic trial pd-gba
current enrol random double-blind sham procedure-
control ascend dose trial moderate-to-sever pd-gba patient
trial includ patient least one mutat receiv
stabl regimen soc treatment escal dose cohort plan
cohort six patient receiv two patient receiv sham procedur
control administ singl inject icm
primari outcom trial includ safeti toler secondari outcom
includ biomark gcase glucer glusph blood csf
exploratori outcom includ clinic efficaci endpoint use parkinson diseas
addit biomark
glucer glusph gcase enzym activ measur csf blood three
month blood addit time point unblind interim analysi
perform patient first cohort complet month treatment
second un-blind interim analysi perform patient second
cohort complet month treatment
consid roll patient receiv sham procedur separ
protocol would administ per fda requir
patient follow total five year monitor safeti select biomark
efficaci
in-licens deliveri technolog encod august
shortli compani incept
licens agreement
licens grant exclus world-wide
licens certain patent manufactur sell treatment diseas
includ limit pd gd whether caus mutat gene
produc enzym use deliv encod
consider licens right licens issu
share common stock privat placement
also oblig accord licens agreement pay
annual mainten fee
mid- high-singl digit royalti percentag net sale licens product
subject reduct specifi circumst
mid-teen low-twenti royalti percentag sublicens fee
may receiv sub-license licens ip
given usual cog highli price medicin neglig low possibl lower
assum cog calcul inclus mid-
high-single-digit royalti would realist estim
model patient
order forecast potenti sale pd-gba indic
first estim sequenc potenti approv
think first approv may happen indic despit fact
trial slightli behind pd-gba trial given ultra-rar indic less
incid infant us less two year life expect
believ gene therapi abl cut regulatori pathway corner
may becom approv four year enter clinic
think zolgensma bla file four year enter clinic
relev compar especi take account zolgensma
use technolog in-licens
overal assum follow sequenc approv
develop clinic success
approv
approv pd-gba
approv
price strategi believ singl price three indic
pd-gba may achiev freedom price-discrimin base
specif therapeut use
due fact indic project first approv believ
could potenti price near direct compar zolgensma
howev may choos price lower anticip launch
broader pd-gba indic significantli higher patient popul
comparison sma diseas zolgensma approv address one
tenth patient popul pd gba mutat
believ cut zolgensma price would reason assumpt
therefor estim launch price indic would like surpris
patient physician importantli payer
model assum incid patient us annual also
assum peak market penetr easili diagnos possibl
patient would elig
also assum split rest world row factor
indic consist row factor expens therapi
assum po indic although open
label studi patient think next studi indic may
pivot
final estim risk-unadjust sale patient popul
model pd-gba patient
second project indic pd-gba estim
total sale gaucher type sale sale sale price launch singl time us gross-to-net discount price current gaucher type patient model provid popul yoy growth preval gaucher patient gaucher patient gaucher patient identifi type month patient identifi type market share price yoy growth discount patient risk adj net sale row gaucher type patient row sale risk adj net sale prevail therapeut
previous mention report dont expect pd
patient would elig gene therapi
mutat gener divid sever mild subset approxim
mild mutat sever base multipl public sever
mutat believ significantli sever clinic manifest includ
age onset surviv dementia depress motor fluctuat other
therefor believ even fda grant broad label
pd patient payer might limit coverag sever patient
believ restrict move payer govern medicar
commerci would best interest organ limit
budget exposur payer may still allow gene treatment enter coverag
word fda/ema approv equal coverag model
purpos impli elig gba-mut pd patient
price decis assum indic includ pd-gba
said price assumpt base averag clinic perform
improv gcase enzym activ
exhibit goal treatment pd-gba
case gcase enzym activ restor level subsequ trial
believ opportun price premium current assumpt
convers subpar result lower expect gcase enzym activ may lower
impli price
assum market penetr pd-gba market patient might
elig pd patient might option time
would administ via icm inject complic surgic
procedur rather short procedur administ outpati set make
market penetr justifi comparison intrathec administ
first-to-market spinraza us market penetr least filth year sinc
also assum customari gross-to-net discount usual much higher
non-gen therapi medicin year-over-year wac price growth assum
averag annual project us growth
assum probabl success pd-gba indicationth
indic simpl explan prove work
assum caus mutat moa would appli pd-
gba indic moreov pd-gba random trial run
unreason figur expect presum pre-registr trial
estim un-risk-adjust sale pd-gba reach think
seemingli high un-risk-adjust figur may point potenti futur valu driver
stock compani move forward develop process risk
adjust improv along way
exhibit parkinson diseas mutat patient model
model patient
third indic patient open label progress studi
expect initi
howev dont think trial prioriti regard clinic regulatori
strategi like sma type first prioriti avexis/nv sma
type initi de-priorit think concentr initi resourc
pd-gba patient
nevertheless assum patient us annual assum
peak market penetr
probabl success trial assum given rel lower
sever neuropath symptom compar longer surviv patient
potenti longer trial factor
forecast risk-unadjust sale indic
peak market penetr
total sale parkinson diseas sale sale sale price launch singl time us gross-to-net discount price current parkinson diseas patient model propel popul yoy growth preval pd patient patient patient sever sever market share pd-gba price yoy growth discount pd patient db candid risk adj net sale row parkinson diseas patient row sale risk adj net sale outperform
preclinical-stag asset frontotempor dementia
grn mutat synucleinopathi gene transfer -synuclein
knockdown expect enter clinic stage
howev valuat purpos includ preclin candid
model appropri establish either potenti sale probabl
success indic drug candid time
updat valuat thesi when/if candid move forward
total sale gaucher type sale sale sale price launch singl time us gross-to-net discount price current gaucher type patient model progress popul yoy growth preval gaucher patient gaucher patient gaucher patient identifi type year old progress patient identifi type market share price yoy growth discount patient risk adj net sale row gaucher type patient row sale risk adj net sale prevail therapeut
found asa abeliovich ph current ceo
orbim silverstein foundat parkinson gba
sinc incept compani appli number patent us
intern base sec file six patent applic pend us
eight patent applic intern jurisdict
patent applic three intern patent applic three us provision
patent applic relat three intern patent
applic five us provision patent applic relat technolog
also patent protect relat technolog licens
patent issu cover licens
agreement
aav-bas gene product configur express codon-optim human
beta-glucocerebrosidas gene encod wild-typ gcase therapeut
protein own one intern patent applic one pend us provision
patent applic contain claim support disclosur direct
